micro-community-banner
 
  • Saved

1yr
Mechanisms and management of CAR T toxicity

Mechanisms and management of CAR T toxicity

Source : https://pubmed.ncbi.nlm.nih.gov/38835382/

Chimeric antigen receptor (CAR) T cell therapies have dramatically improved treatment outcomes for patients with relapsed or refractory B-cell acute lymphoblastic leukemia, large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma,...

CAR T cell therapies offer significant efficacy in hematologic malignancies but come with complex toxicities requiring specialized management to mitigate morbidity and mortality, necessitating thorough understanding and precise clinical guidelines.

  • Saved

1yr
BTK inhibitors in CLL: second-generation drugs and beyond

BTK inhibitors in CLL: second-generation drugs and beyond

Source : https://pubmed.ncbi.nlm.nih.gov/38478390/

BTK inhibitors (BTKis) are established standards of care in multiple B-cell malignancies including chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom macroglobulinemia. The first-generation BTKi ibrutinib demonstrated superiority over standard...

The evolution of BTK inhibitors has progressed from first-generation ibrutinib to second-generation agents with improved cardiovascular profiles. Emerging noncovalent inhibitors like pirtobrutinib address C481S mutations but face challenges with non-C481 variants, driving research into BTK protein degraders.

  • Saved

1yr
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma

Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma

Source : https://pubmed.ncbi.nlm.nih.gov/38705160/

Janssen and Leukemia & Lymphoma Society.

Adding ibrutinib to first-line treatment resulted in superior efficacy in younger mantle cell lymphoma patients with increased toxicity when given after ASCT. Adding ibrutinib during induction and as maintenance should be part of first-line treatment of younger mantle cell lymphoma patients. Whether ASCT adds to an ibrutinib-containing...

  • Saved

1yr
Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions

Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions

Source : https://pubmed.ncbi.nlm.nih.gov/38734670/

Inotuzumab ozogamicin (INO) is an anti-CD22 antibody-drug conjugate that was first evaluated in B-cell lymphomas but was subsequently shown to be highly effective in acute lymphoblastic leukemia (ALL). INO improved...

Inotuzumab ozogamicin (INO) has significantly advanced treatment outcomes in relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), with ongoing studies exploring its expanded role in frontline and salvage therapies.

  • Saved

1yr
Breakthrough Insights in Hematologic Malignancies from EHA 2024: STIMULUS-MDS2 and STARGLOW Trials

Dr. Amer Zeidan from Yale University discusses the STIMULUS-MDS2 study presented at the European Hematology Association meeting in Madrid. This large, randomized phase 3 trial examined the efficacy of combining azacitidine with the anti-TIM3 antibody sabatolimab in patients with high-risk MDS. Although the primary endpoint of overall survival was not met, the combination showed a trend toward improvement in survival and higher complete remission rates.

Dr. Jeremy Abramson from Massachusetts General Hospital shares results from the STARGLOW trial, which evaluated glofitamab with gemcitabine and oxaliplatin in relapsed refractory diffuse large B-cell lymphoma. The trial demonstrated significant improvements in overall survival, progression-free survival, and complete response rates, positioning glofitamab as a promising second-line therapy for DLBCL.